Skip to main content
Erschienen in: Journal of Nuclear Cardiology 5/2022

24.09.2021 | Editorial

How shall we judge a PET flow model?

verfasst von: Nils P. Johnson, MD, MS, K. Lance Gould, MD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Excerpt

Starting over 70 years ago,1 clinicians began quantifying myocardial blood flow to diagnose and guide treatment. During the past seven decades, a large number of tools has been developed, both invasive and non-invasive. The ongoing utility of myocardial blood flow assessment testifies the underlying clinical need. Why does this patient have chest pain or dyspnea? Should I perform coronary angiography or how should I interpret its anatomy? Will the patient benefit from revascularization? And, if yes, which vessels require a procedure? …
Literatur
1.
Zurück zum Zitat Bing RJ, Hammond MM, Handelsman JC, Powers SR, Spencer FC, Eckenhoff JE. The measurement of coronary blood flow, oxygen consumption, and efficiency of the left ventricle in man. Am Heart J 1949;38:1‐24.CrossRef Bing RJ, Hammond MM, Handelsman JC, Powers SR, Spencer FC, Eckenhoff JE. The measurement of coronary blood flow, oxygen consumption, and efficiency of the left ventricle in man. Am Heart J 1949;38:1‐24.CrossRef
2.
Zurück zum Zitat Gould KL, Schelbert HR, Phelps ME, Hoffman EJ. Noninvasive assessment of coronary stenoses with myocardial perfusion imaging during pharmacologic coronary vasodilatation. V. Detection of 47 percent diameter coronary stenosis with intravenous nitrogen-13 ammonia and emission-computed tomography in intact dogs. Am J Cardiol 1979;43:200-208. Gould KL, Schelbert HR, Phelps ME, Hoffman EJ. Noninvasive assessment of coronary stenoses with myocardial perfusion imaging during pharmacologic coronary vasodilatation. V. Detection of 47 percent diameter coronary stenosis with intravenous nitrogen-13 ammonia and emission-computed tomography in intact dogs. Am J Cardiol 1979;43:200-208.
3.
Zurück zum Zitat Schelbert HR, Wisenberg G, Phelps ME, Gould KL, Henze E, Hoffman EJ, et al. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilation. VI. Detection of coronary artery disease in human beings with intravenous N-13 ammonia and positron computed tomography. Am J Cardiol 1982;49:1197-207. Schelbert HR, Wisenberg G, Phelps ME, Gould KL, Henze E, Hoffman EJ, et al. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilation. VI. Detection of coronary artery disease in human beings with intravenous N-13 ammonia and positron computed tomography. Am J Cardiol 1982;49:1197-207.
4.
Zurück zum Zitat Murthy VL, Bateman TM, Beanlands RS, Berman DS, et al. Clinical quantification of myocardial blood flow using PET: Joint position paper of the SNMMI Cardiovascular Council and the ASNC. J Nucl Cardiol 2018;25:269‐97.CrossRef Murthy VL, Bateman TM, Beanlands RS, Berman DS, et al. Clinical quantification of myocardial blood flow using PET: Joint position paper of the SNMMI Cardiovascular Council and the ASNC. J Nucl Cardiol 2018;25:269‐97.CrossRef
6.
Zurück zum Zitat Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med 1996;37:1701‐12.PubMed Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med 1996;37:1701‐12.PubMed
7.
Zurück zum Zitat Sdringola S, Johnson NP, Kirkeeide RL, Cid E, Gould KL. Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers. JACC Cardiovasc Imaging 2011;4:402‐12.CrossRef Sdringola S, Johnson NP, Kirkeeide RL, Cid E, Gould KL. Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers. JACC Cardiovasc Imaging 2011;4:402‐12.CrossRef
8.
Zurück zum Zitat Johnson NP, Gould KL. Physiological basis for angina and ST-segment change PET-verified thresholds of quantitative stress myocardial perfusion and coronary flow reserve. JACC Cardiovasc Imaging 2011;4:990‐8.CrossRef Johnson NP, Gould KL. Physiological basis for angina and ST-segment change PET-verified thresholds of quantitative stress myocardial perfusion and coronary flow reserve. JACC Cardiovasc Imaging 2011;4:990‐8.CrossRef
9.
Zurück zum Zitat Kitkungvan D, Johnson NP, Roby AE, Patel MB, Kirkeeide R, Gould KL. Routine clinical quantitative rest stress myocardial perfusion for managing coronary artery disease: Clinical relevance of test-retest variability. JACC Cardiovasc Imaging 2017;10:565‐77.CrossRef Kitkungvan D, Johnson NP, Roby AE, Patel MB, Kirkeeide R, Gould KL. Routine clinical quantitative rest stress myocardial perfusion for managing coronary artery disease: Clinical relevance of test-retest variability. JACC Cardiovasc Imaging 2017;10:565‐77.CrossRef
10.
Zurück zum Zitat Kitkungvan D, Lai D, Zhu H, Roby AE, Johnson NP, Steptoe DD, et al. Optimal adenosine stress for maximum stress perfusion, coronary flow reserve, and pixel distribution of coronary flow capacity by Kolmogorov-Smirnov analysis. Circ Cardiovasc Imaging 2017;10:e005650. Kitkungvan D, Lai D, Zhu H, Roby AE, Johnson NP, Steptoe DD, et al. Optimal adenosine stress for maximum stress perfusion, coronary flow reserve, and pixel distribution of coronary flow capacity by Kolmogorov-Smirnov analysis. Circ Cardiovasc Imaging 2017;10:e005650.
11.
Zurück zum Zitat Johnson NP, Gould KL. Regadenoson versus dipyridamole hyperemia for cardiac PET imaging. JACC Cardiovasc Imaging 2015;8:438‐47.CrossRef Johnson NP, Gould KL. Regadenoson versus dipyridamole hyperemia for cardiac PET imaging. JACC Cardiovasc Imaging 2015;8:438‐47.CrossRef
12.
Zurück zum Zitat Vasquez AF, Johnson NP, Gould KL. Variation in quantitative myocardial perfusion due to arterial input selection. JACC Cardiovasc Imaging 2013;6:559‐68.CrossRef Vasquez AF, Johnson NP, Gould KL. Variation in quantitative myocardial perfusion due to arterial input selection. JACC Cardiovasc Imaging 2013;6:559‐68.CrossRef
13.
Zurück zum Zitat Franks R, Milidonis X, Schneider T, Sánchez-González J, Plein S, Chiribiri A. Impact of the arterial input sampling location on CMR first-pass myocardial perfusion quantification. JACC Cardiovasc Imaging 2020;13:2693‐5.CrossRef Franks R, Milidonis X, Schneider T, Sánchez-González J, Plein S, Chiribiri A. Impact of the arterial input sampling location on CMR first-pass myocardial perfusion quantification. JACC Cardiovasc Imaging 2020;13:2693‐5.CrossRef
14.
Zurück zum Zitat Gould KL, Kitkungvan D, Johnson NP, Nguyen T, Kirkeeide R, Bui L, et al. Mortality prediction by quantitative PET perfusion expressed as coronary flow capacity with and without revascularization. JACC Cardiovasc Imaging 2021;14:1020‐34.CrossRef Gould KL, Kitkungvan D, Johnson NP, Nguyen T, Kirkeeide R, Bui L, et al. Mortality prediction by quantitative PET perfusion expressed as coronary flow capacity with and without revascularization. JACC Cardiovasc Imaging 2021;14:1020‐34.CrossRef
15.
Zurück zum Zitat Delgado RI, Swint JM, Lairson DR, Johnson NP, Gould KL, Sdringola S. Cost analysis of PET and comprehensive lifestyle modification for the reversal of atherosclerosis. J Nucl Med 2014;55:80‐7.CrossRef Delgado RI, Swint JM, Lairson DR, Johnson NP, Gould KL, Sdringola S. Cost analysis of PET and comprehensive lifestyle modification for the reversal of atherosclerosis. J Nucl Med 2014;55:80‐7.CrossRef
16.
Zurück zum Zitat Kitkungvan D, Johnson NP, Kirkeeide R, Haynie M, Carter C, Patel MB, et al. Design and rationale of the randomized trial of comprehensive lifestyle modification, optimal pharmacological treatment and utilizing PET imaging for quantifying and managing stable coronary artery disease (the CENTURY study). Am Heart J 2021;237:135‐46.CrossRef Kitkungvan D, Johnson NP, Kirkeeide R, Haynie M, Carter C, Patel MB, et al. Design and rationale of the randomized trial of comprehensive lifestyle modification, optimal pharmacological treatment and utilizing PET imaging for quantifying and managing stable coronary artery disease (the CENTURY study). Am Heart J 2021;237:135‐46.CrossRef
17.
Zurück zum Zitat Johnson NP, Sdringola S, Gould KL. Partial volume correction incorporating Rb-82 positron range for quantitative myocardial perfusion PET based on systolic-diastolic activity ratios and phantom measurements. J Nucl Cardiol 2011;18:247‐58.CrossRef Johnson NP, Sdringola S, Gould KL. Partial volume correction incorporating Rb-82 positron range for quantitative myocardial perfusion PET based on systolic-diastolic activity ratios and phantom measurements. J Nucl Cardiol 2011;18:247‐58.CrossRef
18.
Zurück zum Zitat Fournier S, Keulards DCJ, van 't Veer M, Colaiori I, et al. Normal values of thermodilution-derived absolute coronary blood flow and microvascular resistance in humans. EuroIntervention 2021;17:e309-16. Fournier S, Keulards DCJ, van 't Veer M, Colaiori I, et al. Normal values of thermodilution-derived absolute coronary blood flow and microvascular resistance in humans. EuroIntervention 2021;17:e309-16.
Metadaten
Titel
How shall we judge a PET flow model?
verfasst von
Nils P. Johnson, MD, MS
K. Lance Gould, MD
Publikationsdatum
24.09.2021
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 5/2022
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-021-02805-5

Weitere Artikel der Ausgabe 5/2022

Journal of Nuclear Cardiology 5/2022 Zur Ausgabe

Letter to the Editor

Response to JNC-22-024-LE

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.